ExpreS2ion Biotech Holding AB
STO:EXPRS2
ExpreS2ion Biotech Holding AB
Other Current Liabilities
ExpreS2ion Biotech Holding AB
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
ExpreS2ion Biotech Holding AB
STO:EXPRS2
|
Other Current Liabilities
kr23.7m
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Other Current Liabilities
kr199.1m
|
CAGR 3-Years
66%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Other Current Liabilities
kr140.4m
|
CAGR 3-Years
32%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Other Current Liabilities
kr146m
|
CAGR 3-Years
23%
|
CAGR 5-Years
34%
|
CAGR 10-Years
14%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Other Current Liabilities
kr8.8B
|
CAGR 3-Years
54%
|
CAGR 5-Years
9%
|
CAGR 10-Years
31%
|
|
|
BioArctic AB
STO:BIOA B
|
Other Current Liabilities
kr505.1m
|
CAGR 3-Years
132%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
ExpreS2ion Biotech Holding AB
Glance View
Expres2ion Biotech Holding AB engages in the development of a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer. The company is headquartered in Helsingborg, Skane and currently employs 29 full-time employees. The company went IPO on 2016-07-29. The firm specializes in developing cell lines and processes based on a non-viral Drosophila S2 cells expression system. The firm's ExpreS2 recombinant protein expression platform supports all phases of drug discovery, research and development and manufacturing. ExpreS2 is a non-viral insect cell expression system that establishes stable polyclonal pools that provide high-protein expression levels without selection pressure. The system is designed for transient or stable transfections using vector deoxyribonucleic acid containing a hybrid promoter. The company also ensures high cell density without aggregation or toxic metabolite build-up issues. Through the joint venture AdaptVac ApS, the Company applies a Plug-and-Play Virus Like Particle technology for development of therapeutic and prophylactic vaccines within oncology, infectious diseases and immunological disorders.
See Also
What is ExpreS2ion Biotech Holding AB's Other Current Liabilities?
Other Current Liabilities
23.7m
SEK
Based on the financial report for Dec 31, 2025, ExpreS2ion Biotech Holding AB's Other Current Liabilities amounts to 23.7m SEK.
What is ExpreS2ion Biotech Holding AB's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
11%
Over the last year, the Other Current Liabilities growth was -19%. The average annual Other Current Liabilities growth rates for ExpreS2ion Biotech Holding AB have been 11% over the past three years , 11% over the past five years .
